Five Prime Therapeutics Prices Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq: FPRX) announced today the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price of $12.50 per share for an aggregate offering of $37.5 million, before underwriting discounts, commissions and estimated expenses. All of the shares of common stock are being offered by Five Prime. In addition, Five Prime has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock at the offering price. The offering is expected to close on February 12, 2014, subject to customary closing conditions.

Jefferies LLC, BMO Capital Markets and Wells Fargo Securities, LLC are acting as joint book-running managers and Guggenheim Securities, LLC is acting as a co-manager for the offering.

A registration statement related to the common stock being offered by Five Prime was declared effective by the Securities and Exchange Commission on February 6, 2014. The offering is being made only by means of a final prospectus, which is part of the effective registration statement. Copies of the final prospectus, when available, may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: [email protected]; or BMO Capital Markets, Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, telephone: (800) 414-3627, e-mail: [email protected]; or Wells Fargo Securities, LLC, Attention: Capital Markets Client Support, 1525 West W.T. Harris Boulevard, NC0675, Charlotte, NC 28262, telephone: (800) 326-5897, e-mail: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Five Prime Therapeutics, Inc.

Five Prime is a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases. Five Prime has developed a library of more than 5,700 human extracellular proteins. Five Prime screens this comprehensive library with its proprietary high-throughput protein screening technologies to identify new targets for protein therapeutics.

CONTACT: COMPANY CONTACT:
         Amy Kendall
         Corporate Communications
         415-365-5776
         [email protected]

You May Also Be Interested In

• Latigo Biotherapeutics seeks to raise up to $288m in IPO
• Heritage Global acquires Boston Note Company to expand into seller notes
• Esquire Financial completes acquisition of Signature Bancorporation